---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-028892"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:32:26.572584+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Corcept Q1 revenue $164.9M (+5% YoY); raises 2026 guidance to $950-1050M; Lifyorli approved

## Summary
- Revenue $164.9M, up 5% YoY from $157.2M. Net loss $31.8M vs net income $20.5M in Q1 2025 due to launch costs.
- 2026 revenue guidance raised to $950-$1,050M (from prior range).
- FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026; NCCN preferred regimen.
- Cash and investments $515.4M at March 31, 2026. Expect return to profitability in Q2 2026.
- ROSELLA trial results published in The Lancet; BELLA, SYNERGY, MONARCH, DAZALS trials ongoing.

## SEC filing metadata
- accession: 0001628280-26-028892
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828026028892/0001628280-26-028892-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828026028892/cort-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-028892
- JSON: https://secwatch.observer/filing/0001628280-26-028892.json
- Plain text: https://secwatch.observer/filing/0001628280-26-028892.txt

## Key facts
- Earnings Releases
  CORCEPT THERAPEUTICS INC reported the quarter ended March 31, 2026 results: revenue $164.9 million, net income Net loss of $31.8 million, EPS Net loss per common share (diluted) was $0.30. Guidance raised.
  - Period: the quarter ended March 31, 2026
  - Revenue: $164.9 million
  - Net income: Net loss of $31.8 million
  - EPS: Net loss per common share (diluted) was $0.30
  - Guidance: raised
  - Result: reported results
  source text: • Revenue of $164.9 million, compared to $157.2 million in first quarter 2025 • Increase in 2026 revenue guidance to $950 – $1,050 million • Net loss of $31.8 million, compared to net income of $20.5 million in first quarter 2025 • Cash and investments of $515.4 million at March 31, 2026 • LifyorliTM (relacorilant) approved by FDA in March 2026 for the treatment of patients with platinum-resistant ovarian cancer REDWOOD CITY, Calif., (April 30, 2026) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2026. Financial Results Corcept’s first quarter 2026 revenue was $164.9 million, compared to $157.2 million in the first quarter of 2025. First quarter 2026 operating expenses were $214.5 million, compared to $153.8 millio
  evidence_url: https://www.sec.gov/Archives/edgar/data/1088856/000162828026028892/0001628280-26-028892-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.